Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of CAM2029 in Acromegaly
2024-510667-33-00Phase 3Completed
- Sponsor
- Camurus
- Start
- Apr 2024
- Modality
- Peptides
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of octreotide hydrochloride in acromegaly, sponsored by Camurus. Primary endpoint: Adverse events characterization (main and extension parts). Started Apr 2024; status: completed.
02
Drugs
octreotide hydrochloride
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2024-510667-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510667-33-00.